Supply terms
These terms apply across the PharmaTradz catalogue. They are set out here once, in full, rather than repeated on every product page — so buyers get the complete position in one place and can raise an RFQ knowing what is standard and what is negotiable.
Regulatory dossiers
Dossiers are supplied in the format the destination market requires. Across our manufacturer base we work in three:
| Format | Typically required by |
|---|---|
| CTD Common Technical Document |
The general international format, used across most markets that follow ICH structure. |
| ACTD ASEAN Common Technical Dossier |
ASEAN member states and several markets that have aligned to the ASEAN structure. |
| EU-CTD European Common Technical Document |
European Union filings and markets that accept or mirror EU submissions. |
Which format applies is determined by your destination market, not by the product. Tell us the country in your RFQ and we confirm the required format, whether a bioequivalence study is needed, and whether an existing dossier can be licensed in your name rather than developed from scratch.
Market availability
All markets are open for discussion, for every product in the catalogue. We hold multiple manufacturing sources for the same molecule, so where one manufacturer cannot serve a given market — because of registration status, site approvals or existing exclusivity — another generally can.
This means a product listing is not a statement that it is already registered in your country. It is a statement that we can source it. The registration position for your specific market is confirmed at RFQ stage, alongside which of our sources holds the relevant approvals.
Shelf life
A minimum of 80% of total shelf life remaining is offered as standard on every product. This is the baseline, not a best case.
Where a market or tender requires more than 80% remaining, say so in your RFQ — it affects which batches can be allocated and occasionally the price, so it is better raised before quotation than after.
Minimum order quantities
MOQ is set by dosage form, since pack economics and line changeover costs differ sharply between an injectable and an oral solid:
| Dosage form | Indicative MOQ |
|---|---|
| Injectables injections, infusions, vials, ampoules, prefilled syringes, lyophilised powders for injection |
50,000 units |
| Oral solids tablets, capsules, caplets, sachets, granules, lozenges |
200,000 units |
| All other forms creams, ointments, drops, syrups, suspensions, powders, gummies, devices |
Adjusted to a minimum order value of USD 5,000 per product |
These are indicative. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market — a market requiring country-specific artwork or a dedicated batch will generally carry a higher minimum than stock supply of an existing presentation.
What to include in an RFQ
The more of this you provide up front, the fewer rounds it takes to get to a firm price:
- Destination market — determines dossier format, registration route and which sources qualify
- Product, strength and dosage form
- First order quantity and estimated annual volume
- Whether you need a dossier, or the product is already registered in your name
- Pack presentation, artwork and language requirements
- Incoterms and any shelf-life requirement above the 80% standard
Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities in the exporting and importing countries.
